ArticleCureus2025
Aggressive Clinical Course of Mucinous Tubular and Spindle Cell Renal Cell Carcinoma Following CT-Guided Ablation: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucinous tubular and spindle cell renal cell carcinoma (MTSRCC) is an uncommon renal epithelial neoplasm historically regarded as indolent. We describe an 81-year-old woman with an incidentally detected 1.4 cm right interpolar renal mass, biopsied and ablated percutaneously, with histology confirming World Health Organization/International Society of Urological Pathology grade 2 (WHO/ISUP grade 2) MTSRCC. Within three months, she developed extensive right renal vein thrombosis with propagation to the inferior vena cava (IVC) and right atrium, initially considered treatment-related. Despite systemic anticoagulation, she demonstrated rapid progression with innumerable hepatic metastases on magnetic resonance cholangiopancreatography (MRCP) six months after ablation and died shortly thereafter. This report underscores that MTSRCC can behave aggressively, with venous tumor thrombus and an explosive metastatic dissemination. It also highlights the diagnostic challenges distinguishing bland from malignant thrombus, as well as the nuances of managing small renal masses in frail older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.